Reneo Pharmaceuticals Inc   (RPHM)
Other Ticker:  
Price: $1.6400 $0.03 1.863%
Day's High: $1.66 Week Perf: 0.00
Day's Low: $ 1.61 30 Day Perf: -2.96 %
Volume (M): 311 52 Wk High: $ 11.30
Volume (M$): $ 510 52 Wk Avg: $6.02
Open: $1.61 52 Wk Low: $0.98

 Market Capitalization (Millions $) 55
 Shares Outstanding (Millions) 34
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -67
 Cash Flow (TTM) (Millions $) -113
 Capital Exp. (TTM) (Millions $) 1

Reneo Pharmaceuticals Inc
Reneo Pharmaceuticals Inc is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of therapies for patients with rare, genetic diseases. The company's focus is primarily on mitochondrial diseases, which are a group of genetic disorders that affect the way cells produce energy. These diseases are caused by mutations in genes that result in defects in the function of the mitochondria, which are organelles responsible for energy production. The consequences of these mutations can be severe, leading to a wide range of symptoms and complications.

The company was founded in 2015 and is headquartered in San Diego, California. Reneo Pharmaceuticals' management team has a strong track record in the development of therapeutics for mitochondrial diseases. The company has a team of experienced industry professionals who are passionate about the development of therapies for patients with rare diseases.

Reneo's lead product candidate, REN001, is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that is being developed as a potential treatment for primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). REN001 has received orphan drug designation from the US Food and Drug Administration (FDA) for both indications, and the company is currently conducting clinical trials to assess its safety and efficacy. The trials are expected to be completed by the end of 202

Reneo Pharmaceuticals' pipeline also includes other potential treatments for mitochondrial diseases, including a second-generation PPARd agonist and a mitochondria-targeted compound. The company is committed to developing novel therapies for patients with rare, genetic diseases and is working to advance the science of mitochondrial biology to improve the lives of those affected by these conditions.

   Company Address: 18575 Jamboree Road, Suite 275-S Irvine 92612 CA
   Company Phone Number: 283-0280    Stock Exchange / Ticker: NASDAQ RPHM
   RPHM is expected to report next financial results on March 26, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Reneo Pharmaceuticals Inc

RPHM's Fiscal Time-Frame Ending Q3 2023 Revealed: Major Growth Impacts Major Pharmaceutical Preparations Industry

The Major Pharmaceutical Preparations industry witnesses keen analysis from veterans who closely monitor financial reports and performance indicators. As we delve into the details of the third quarter of 2023, one prominent player, Reneo Pharmaceuticals Inc (RPHMsn), caught the attention of analysts due to its operating shortfall and absence of top-line figures. This article will examine the intriguing facts surrounding Reneo Pharmaceuticals and its future prospects.
Operating Shortfall in Q3 2023:
Reneo Pharmaceuticals Inc reported an operating shortfall of $-20.888 million for the period from July to September 2023. This figure marks a significant increase from the corresponding period in 2022, where the operating shortfall stood at $-13.84 million. The widening gap has raised concerns among industry experts, who are eagerly awaiting news on the company's top-line.

Reneo Pharmaceuticals Inc

Revolutionary Cost-Cutting Strategies Mitigate Business Expenses Surge for Reneo Pharmaceuticals Inc in 2023 Q2

The stock market has always been a source of excitement and opportunity for investors, and the recent reporting cycle from April to June 2023 has certainly provided plenty of interesting developments. One sector that has been in the spotlight is Major Pharmaceutical Preparations, with several corporations making significant announcements.
Among these corporations is RPHM, which recently reported an operating deficit of $-21.039 million for the second quarter of 2023. While this may seem like a negative outcome at first glance, it's important to put it into perspective. Comparing it to the second quarter of 2022, where the operating deficit was $-12.431 million, we can see that RPHM is making progress despite the challenges faced.

Reneo Pharmaceuticals Inc

First Quarter Report 2023 Reveals Exciting Insights

Investing in the stock market can be a daunting task, but with in-depth research and information, you can make informed decisions to invest in the most promising companies. Reneo Pharmaceuticals Inc, a major player in the healthcare sector, has recently released its first-quarter report for 2023, which has been the talk of the market.
According to the report, Reneo Pharmaceuticals Inc recorded a cumulative net loss of $-54 million resulting in a negative return on investment of -50.52%. While these numbers do not paint a positive picture, it is important to note that the company is still in its expanding stage. The deficit has widened but let us not forget that growth never comes easy.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com